Pasithea Therapeutics Corp.
A privately held company
We are at the forefront of research focusing on development of therapies for diseases of the central nervous system (CNS). With an experienced team of experts in the fields of neuroscience and pharmacology, Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.